The Neurotech Newsletter

The Neurotech Newsletter by Carter Sciences delivers bi-weekly, high-signal updates across neurotechnology, covering funding, regulation, clinical progress, launches, partnerships, and hiring. Built for anyone involved or interested in Neuotech.

Recent Updates

1. Pharaoh Neuro is addressing a significant medical gap: "We have dialysis for the blood, but not for the fluid around the brain." Post-haemorrhagic stroke care is currently lacking, and Pharaoh Neuro aims to bridge this gap.

   The Brain Has Electricity. Pharaoh Neuro Is Building the Plumbing.

2. A $500M investment led by Jeff Bezos: This funding focuses on reverse-engineering the brain's core algorithm. While their product is still in development, the company boasts a valuation of $2.5B. Other notable mentions include Medtronic's growth and Paradromics' brain-chip implantation in humans.

   Full edition here

3. Neurotech Transaction Insights: Following a comprehensive assessment of neurotech transactions, it's noted that much funding is concentrated among a few key players, while noteworthy research is often sustained on grants.

   Notes from a Spreadsheet

4. Historical Analysis of Neurotech Financing: The recent series delves into two decades of neurotech funding trends, revealing where financing is flowing and highlighting the disparity between emerging technologies and established players.

   Neurotech Money, Part 1: The Technologies

5. Interview Highlights: An in-depth discussion with Jordi Parramon reveals insights from his extensive tenure at Boston Scientific, analyzing the evolution of procedures in the neuromodulation sector and the industry's trajectory.

   From Microchips to Market Maps: Jordi Parramon on What Neurotech Has Learned

Conclusion: The Neurotech Newsletter aims to provide relevant updates and essential discussions centered on neurotechnology advancements, funding trends, and industry insights.